

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

## **BBI LIFE SCIENCES CORPORATION** **BBI生命科學有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1035)**

### **HIGH CONCENTRATION OF SHAREHOLDING**

This announcement is made by the Company at the request of the Stock Exchange in respect of the concentration of the shareholding of the Company in the hands of a limited number of shareholders as at 13 April 2015.

**In view of the high concentration of shareholding in a small number of shareholders, shareholders and prospective investors should be aware that the price of the shares of the Company (“Shares”) could fluctuate substantially even with a small number of shares traded, and should exercise extreme caution when dealing in the Shares.**

This announcement is made at the request of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) in respect of the concentration of the shareholding of BBI Life Sciences Corporation (the “Company”) in the hands of a limited number of shareholders of the Company (the “Shareholders”) as at 13 April 2015.

### **HIGH CONCENTRATION OF SHAREHOLDING**

The Company noted that an announcement has been published by the Securities and Futures Commission (the “SFC”) on 29 April 2015 (the “SFC Announcement”).

As disclosed in the SFC announcement, the SFC has recently completed an enquiry into the shareholding of the Company. The SFC’s findings suggested that as at 13 April 2015, 13 shareholders held an aggregate of 94,606,000 Shares, representing 18.03% of the issued Shares. Such shareholding, together with 310,655,924 Shares (representing 59.21% of the issued Shares) and 82,841,176 Shares (representing 15.79% of the issued Shares) respectively held by 2 substantial shareholders of the Company, namely, The Family of Wang Qisong and Qiming Ventures, represented 93.03% of the issued Shares as at 13 April 2015. Therefore, only 36,560,000 Shares (representing 6.97% of the issued Shares) were held by other shareholders.

The information above is extracted from the SFC Announcement and the Company has not independently verified such information. Please also refer to the SFC Announcement for other information.

As set out in the SFC Announcement, the shareholding structure of the Company as at 13 April 2015 was as follows:

	<b>Number of Shares held</b> <i>(Shares)</i>	<b>% of total number of issued Shares</b> <i>(%)</i>
The Family of Wang Qisong <i>(Note 1)</i>	310,655,924	59.21
Qiming Ventures <i>(Note 2)</i>	82,841,176	15.79
A group of 13 shareholders	94,606,000	18.03
Other shareholders	<u>36,560,000</u>	<u>6.97</u>
<b>Total</b>	<b><u>524,663,100</u></b>	<b><u>100.00</u></b>

*Note 1:* The Family of Wang Qisong, comprising Wang Qisong, Wang Jin, Wang Luojia and others, owns either directly or indirectly via 2 family trusts, LJ Peace Ltd, LJ Venture Ltd, and LJ Hope Ltd, which in turn held 184,156,346 Shares, 118,049,745 Shares, and 8,449,833 Shares respectively, representing 35.10%, 22.50%, and 1.61% of the issued Shares. Wang Qisong is the settlor for the 2 family trusts, and his 2 daughters Wang Jin and Wang Luojia, as well as their children, are the beneficiaries. Wang J Family Trust owns 51.15% of LJ Peace Ltd and 50% of LJ Venture Ltd. Wang L Family Trust owns 48.85% of LJ Peace Ltd and 50% of LJ Venture Ltd. Wang Luojia and her spouse Mai Jun each owns 50% of LJ Hope Ltd. Wang Qisong, Wang Luojia, and Wang Jin are Executive Directors of the Company, and are persons acting in concert.

*Note 2:* Qiming Venture Partners II, L.P., Qiming Venture Partners II-C, L.P., and Qiming Managing Directors Fund II, L.P. (collectively Qiming Ventures) held 75,161,799 Shares, 6,585,871 Shares, and 1,093,506 Shares respectively, representing 14.33%, 1.26%, and 0.21% of the issued Shares. Qiming Venture Partners II, L.P., Qiming Venture Partners II-C, L.P., and Qiming Managing Directors Fund II, L.P. are persons acting in concert.

The Company was listed on the main board of the Stock Exchange of Hong Kong Limited on 30 December 2014 by offering a total of 131,166,000 Shares, equivalent to 25% of the issued Shares, at \$1.75 per Share. On that day, price of the Shares closed at \$1.75 with trading volume of 58,054,500 Shares. Since then, the closing price of the Shares fluctuated within a narrow range. During the period from 31 December 2014 to 1 April 2015, the closing price of the Shares rose slightly from \$1.75 to \$1.93 with an average daily trading volume of 3,096,968 Shares.

During the period from 2 April 2015 to 23 April 2015, the closing price and trading volume of the Shares increased significantly. The closing price surged 105.7% from \$1.93 to \$3.97 with an average daily trading volume of 7,384,038 Shares.

Since its listing date, the Company made, inter alia, the following announcements:

- On 30 January 2015, the Company issued a profit alert stating that it expected to record an increase of approximately 8%-12% in its net profit for the year ended 31 December 2014 as compared to the corresponding period in 2013, before taking into account the non-recurring gains and expenses. After taking into account such non-recurring gains and expenses, the net profit for the year ended 31 December 2014 may decrease by approximately 12-16% as compared to that for the corresponding period in 2013.
- On 18 March 2015, the Company announced its annual results for the year ended 31 December 2014, reporting a net profit of approximately RMB35.98 million, down 15% from that for the corresponding period in 2013. After deducting non-recurring one-off gains and expenses, the adjusted net profit was approximately RMB46.93 million, representing an increase of 10.8% from that for the corresponding period in 2013.

As at 28 April 2015, the share price of the Company closed at \$3.46, representing an increase of 79.3% from the closing price on 1 April 2015 or an increase of 97.7% since its first day of listing.

## **PUBLIC FLOAT**

Based on the information available and to the best knowledge of the board of Directors after making all reasonable enquiries of its connected persons, the Company confirms that not less than 25% of the Company's issued Shares are in the hands of the public as at 13 April 2015 and the date of this announcement and the Company is able to comply with the public float requirement under the Rules Governing the Listing of Securities on the Stock Exchange.

**In view of the high concentration of shareholding in a small number of shareholders, shareholders and prospective investors should be aware that the price of the Shares could fluctuate substantially even with a small number of shares traded, and should exercise extreme caution when dealing in the Shares.**

On behalf of the Board of  
**BBI Life Sciences Corporation**  
**Wang Qisong**  
*Chairman*

Hong Kong, 29 April 2015

*As at the date of this announcement, the executive directors of the Company are Mr. WANG Qisong, Ms. WANG Luojia, and Ms. WANG Jin; the non-executive director of the Company is Mr. HU Xubo; and the independent non-executive directors of the Company are Mr. XIA Lijun, Mr. HO Kenneth Kai Chung and Mr. LIU Jianjun.*